HUMA News and Press, Humacyte Inc. From 06/09/25

2025-06-09 01:57:15 ET Introduction Humacyte's stock ( HUMA ) is down 22% since my Sell rating in March. The company markets Symvess (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma. Notably, Symvess is only indicated in cases wher...

DURHAM, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced that its abstract on the V007 Pivotal Phase 3 clinical trial of the acellu...

DURHAM, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and ...

2025-05-14 14:31:18 ET Incannex Rockets 860% on Drug Progress for Sleep Apnea Incannex Healthcare Inc. ( IXHL ) catapulted over 860% to lead the PRISM Emerging Psychedelics Index after announcing it had completed patient dosing in the Phase 2 portion of its pivotal Phase 2/3...

2025-05-13 14:30:44 ET Village Farms Soars 31% on Produce Spinout and Global Cannabis Refocus Village Farms International Inc. ( VFF ) surged over 30% to lead the PRISM Emerging Cannabis Index after announcing a transformative transaction to spin off its U.S. Fresh Produce b...

2025-05-13 14:29:05 ET Humacyte, Inc. (HUMA) Q1 2025 Earnings Conference Call May 13, 2025 08:30 AM ET Company Participants Thomas Johnson - Director-Corporate Communications, LifeSci Advisors, IR Laura Niklason - Founder, President and Chief Executive Officer Da...

2025-05-13 07:33:04 ET More on Humacyte Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript Humacyte: Doubts Cast Around Efficacy Of Symvess May Be Hard To Dispel Humacyte: Symvess' Approval And Launch Are Just The First Steps To Adoption (Downgrade) ...

- Commenced market launch and first commercial sales of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma - - Total revenues of $517,000 for quarter from sales and collaborative research agreement – - Completed public o...

urban-gro Inc. (UGRO) is expected to report for quarter end 2025-03-31 Karman Holdings Inc. (KRMN) is expected to report $0.02 for Q1 2025 PyroGenesis Inc Com (PYRGF) is expected to report for quarter end 2025-03-31 GeoVax Labs Inc. (GOVX) is expected to report $-0.59 for Q1 2025 ...

2025-05-12 14:29:36 ET More on Humacyte Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript Humacyte: Doubts Cast Around Efficacy Of Symvess May Be Hard To Dispel Humacyte: Symvess' Approval And Launch Are Just The First Steps To Adoption (Downgrade) ...